Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

San Francisco, California

Cancer surgery and procedure trials in San Francisco, CA

61 cancer surgery and procedure studies are recruiting participants at sites in San Francisco as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

San Francisco at a glance

  • 61 studies are recruiting at a site in San Francisco.
  • By phase: Early Phase 1 (2), Phase 1 (5), Phase 1/2 (4), Phase 2 (15), Phase 2/3 (1), Phase 3 (21), No phase (4), Observational (9). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (50), government (11).
  • By research area: Lymphoma (17), Breast Cancer (13), Prostate Cancer (13), Lung Cancer (10), Pancreatic Cancer (6), Melanoma (2).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in San Francisco

Basic details from each study's public record (the 30 most recently updated of 61). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    California Pacific Medical Center-Pacific Campus
    Registry record
    NCT07391774 · updated
  2. Pulsed Electric Field Ablation for Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    University of California, San Francisco
    Study site
    University of California San Francisco
    Registry record
    NCT07487844 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    California Pacific Medical Center-Pacific Campus
    Registry record
    NCT06058377 · updated
  4. Mirai-MRI: Validation of AI Models for Breast Cancer Risk

    • No phase
    • Ages 40 to 89
    • Female participants
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT07121972 · updated
  5. Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT05964504 · updated
  6. Distance-Based Exercise to Preserve Function and Prevent Disability

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT07059884 · updated
  7. Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT06774027 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Lung cancer studies recruiting in San Francisco

  1. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UCSF Medical Center-Mission Bay
    Registry record
    NCT04665739 · updated
  2. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT06498635 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    California Pacific Medical Center-Pacific Campus · Kaiser Permanente-San Francisco
    Registry record
    NCT04267848 · updated
  4. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT04181060 · updated
  5. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    California Pacific Medical Center-Pacific Campus · Kaiser Permanente-San Francisco
    Registry record
    NCT06031688 · updated
  6. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    California Pacific Medical Center-Pacific Campus
    Registry record
    NCT06116682 · updated
  7. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Kaiser Permanente-San Francisco · Veterans Affairs Medical Center - San Francisco
    Registry record
    NCT06616584 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Prostate cancer studies recruiting in San Francisco

  1. 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT07145177 · updated
  2. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT06931340 · updated
  3. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT05946213 · updated
  4. Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

    • Early Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Robert Flavell, MD, PhD
    Study site
    University of California, San Francisco
    Registry record
    NCT05851365 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Melanoma studies recruiting in San Francisco

  1. Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT07148245 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in San Francisco, CA on ClinicalTrials.gov.

Lymphoma studies recruiting in San Francisco

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UCSF Medical Center-Mission Bay
    Registry record
    NCT06317662 · updated
  2. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    UCSF Medical Center-Mission Bay
    Registry record
    NCT04726241 · updated
  3. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UCSF Medical Center-Mission Bay
    Registry record
    NCT04546399 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT05675410 · updated
  5. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT03150693 · updated
  6. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT07215910 · updated
  7. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT07321652 · updated
  8. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UCSF Medical Center-Mission Bay
    Registry record
    NCT06124157 · updated
  9. ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Michael Spinner, MD
    Study site
    University of California, San Francisco
    Registry record
    NCT07021989 · updated
  10. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    UCSF Medical Center-Parnassus
    Registry record
    NCT05633615 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Francisco, CA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in San Francisco

  1. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    California Pacific Medical Center-Pacific Campus
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Ask about studies near San Francisco

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call